The KEAP1-NRF2 System in Cancer

• Published in: Frontiers in oncology Vol. 7; p. 85
• Main Authors: Taguchi, Keiko, Yamamoto, Masayuki
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.05.2017
• Subjects: cancer; cancer therapy; KEAP1; metabolic reprogramming; NRF2; Oncology; cancer therapy; KEAP1; cancer; NRF2; metabolic reprogramming
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2017.00085

Cancer cells first adapt to the microenvironment and then propagate. Mutations in tumor suppressor genes or oncogenes are frequently found in cancer cells. Comprehensive genomic analyses have identified somatic mutations and other alterations in the or genes and in well-known tumor suppressor genes or oncogenes, such as , and , in various types of cancer. Aberrant NRF2 activation in cancer cells occurs through somatic mutations in the or gene as well as through other mechanisms that disrupt the binding of KEAP1 to NRF2. Unregulated NRF2 confers on cancer cells high-level resistance to anticancer drugs and reactive oxygen species (ROS) and directs cancer cells toward metabolic reprogramming. Therefore, NRF2 has been studied as a therapeutic target molecule in cancer. Two strategies have been used to target NRF2 via therapeutic drugs: inhibition of NRF2 and induction of NRF2. NRF2 inhibitors may be effective against NRF2-addicted cancer cells in which NRF2 is aberrantly activated. These inhibitors have not yet been established as NRF2-targeted anticancer drugs for the treatment of human cancers. Diagnosis of NRF2 activation could facilitate the use of NRF2 inhibitors for the treatment of patients with NRF2-addicted cancers. Conversely, NRF2 inducers have been used or are being developed for non-cancer diseases. In addition, NRF2 inducers may be useful for cancer chemotherapy in combination with conventional anticancer agents or even NRF2 inhibitors.